Hainan Haiyao plans to reduce its holdings of China Antibody by no more than 68 million shares

NightAirdropper · 2026-04-05T11:50:48+00:00

Beijing Business Daily News (Reporter Ding Ning) reported that on the evening of April 3, Hainan Haiyao (000566) issued an announcement stating that the company plans to reduce its holdings of shares in China Antibody Pharmaceutical Co., Ltd. (HK03681, hereinafter referred to as “China Antibody”) by no more than 68 million shares, through centralized bidding and block trades (representing no more than 5% of its total share capital). The announcement shows that China Antibody is a company with invested enterprises as shareholders. Hainan Haiyao holds 15888.21 million shares of China Antibody, accounting for 11.46% of its total share capital. To optimize the company’s asset structure and improve the liquidity and utilization efficiency of its assets, the company plans to dispose of a total of no more than 68 million shares of China Antibody held by it at an appropriate time (representing no more than 5% of the total number of shares of China Antibody).

NightAirdropper

2026-04-05 11:50:48

Beijing Business Today News (Reporter Ding Ning) On the evening of April 3, Hainan Haiyao (000566) issued an announcement stating that the company plans to reduce its holdings of China Antibody Pharmaceutical Co., Ltd. (HK03681, hereinafter referred to as “China Antibody”) by no more than 68 million shares through block trades and bulk transactions via centralized bidding (the proportion of the company’s total issued share capital shall not exceed 5%).

The announcement shows that China Antibody System is a company with a participating investment. Hainan Haiyao holds 158.8821 million shares of China Antibody, accounting for 11.46% of its total issued share capital. In order to optimize the company’s asset structure and improve asset liquidity and usage efficiency, the company plans, at appropriate times, to dispose of an aggregate number of China Antibody shares it holds of no more than 68 million shares (accounting for no more than 5% of the total number of China Antibody shares).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.